NVCT - Nuvectis Pharma, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
17.82
+0.29 (+1.65%)
At close: 04:00PM EDT
Stock chart is not supported by your current browser
Previous close17.53
Open17.59
Bid16.86 x 1100
Ask17.79 x 800
Day's range17.47 - 17.82
52-week range6.21 - 17.82
Volume48,770
Avg. volume35,347
Market cap285.252M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Nuvectis Pharma Announces FDA Clearance of NXP900 IND

    Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (“FDA”) cleared the Company's Investigational New Drug Application (“IND”) for NXP900, which includes the Phase 1 clinical trial protocol. “The IND

  • GlobeNewswire

    Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

    Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR Conference Demonstrates Potential of NXP800 in the Treatment of Cholangiocarcinoma FORT LEE, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medici

  • GlobeNewswire

    Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

    FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is May 2nd, 2023. The complete, corrected release follows: Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, C

  • GlobeNewswire

    Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

    FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City. EventH.C. Wainwright BioConnect Investor Conferenc

  • GlobeNewswire

    Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

    NXP800 demonstrated robust antitumor activity in two patient-derived xenograft (“PDX”) models of cholangiocarcinomaResearch conducted by investigators from the Mayo Clinic in Rochester, MN Fort Lee, NJ, April 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided

  • GlobeNewswire

    Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

    Phase 1b study builds on highly consistent preclinical and Phase 1a dataFort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study for NXP800 in platinum-resistant, ARID1a-mutated ovarian carcinoma. The Phase 1

  • GlobeNewswire

    Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

    Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Flori

  • GlobeNewswire

    Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

    FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference. Event 35th Annual Roth Conference Date March 14, 2023 Time 12:00 PM Pacific Time (3:00 PM Easter

  • GlobeNewswire

    Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

    NXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian CarcinomaENGOT and GOG Foundation to Lead the NXP800 Phase 1b Clinical Trial in Ovarian Cancer (Study Commencement Pending) NXP900 IND Submission and Phase 1 Study Commencement Expected in 1H 2023 FORT LEE, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ

  • GlobeNewswire

    Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

    Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatinFort Lee, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights fr

  • GlobeNewswire

    Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

    Co-corresponding authors: Charles Sawyers (Memorial Sloan Kettering Cancer Center) and Bin-Zhi Qian (University of Edinburgh)FORT LEE, N.J, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a publication in the Journal of Experimental Medicine (“JEM”) f

  • GlobeNewswire

    Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

    Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander (University of California San Diego, San Diego, CA) will be the co-GOG Foundation Trial Leads in the US Fort Lee, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovat

  • GlobeNewswire

    FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

    Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma. “We are very pleased with the

  • GlobeNewswire

    Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

    The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 Investigational New Drug Application(“IND”)-enabling studies for NXP900 are ongoing, submission of IND or equivalent expected in Q1 2023Positive preclinical data for NXP800 in an ARID1a-mutated gastric cancer modelNXP800 poster presented at the 2022 ENA Conference on the validation of biomarkers supporting the clinical development of NXP800 NXP90

  • GlobeNewswire

    Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

    FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the publication of abstracts for two posters that will be presented at the upcoming 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (“2022 ENA”), taking place from October 26t

  • GlobeNewswire

    Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

    FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference. EventRoth Inaugural Healthcare Opportunities ConferenceDateOctober 6, 2022Time8:15 a.m. ETLocationNew York About

  • GlobeNewswire

    Nuvectis Pharma Announces Formation of a Scientific Advisory Board

    FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in translational science and clinical research that will help guide the Company’s research and development strategy. “As the evidence suppo

  • GlobeNewswire

    Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

    ARID1a- mutated gastric carcinoma model (SNU-1) Tumor volumes over time FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. “Following the strong preclinical proof of concept in A

  • GlobeNewswire

    Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

    FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences in September. EventHC Wainwright 24th Annual Global Investment ConferenceDateSeptember 13, 2022Time10:3

  • GlobeNewswire

    Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

    NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in the Clinical ProgramNXP900 IND-Enabling Work Progressing as Planned, Expected Completion by Year-End 2022Recently Completed Private Placement Extends Cash Runway into H2 2024 FORT LEE, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biophar

  • GlobeNewswire

    Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

    Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced private placement of 1,924,689 shares of common stock (or pre-funded warrants in lieu thereof) for gross proceeds of approximately $15.9 million, before deducting t

  • GlobeNewswire

    Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement

    Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, announced today that it has entered into definitive agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1,924,689 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price

  • GlobeNewswire

    Nuvectis Pharma Announces FDA Clearance of IND for NXP800

    FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (“FDA”) cleared the Company's Investigational New Drug Application (“IND”) for NXP800, which includes the Phase 1 clinical trial protocol. The NXP800 Phase 1 clinical trial is compr

  • GlobeNewswire

    Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

    FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12th, 2022 at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists from the Pediatric Solid Tumour Biology and Th